XML 51 R39.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]            
Number of reportable segments | segment         1  
Number of operating segments | segment         1  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Total revenues $ 22,241   $ 10,797   $ 35,434 $ 19,901
Cost of product sales 0   176   0 446
Cost of manufacturing services 8,906   2,647   14,306 4,493
Research and development 40,791   51,732   80,489 97,760
Selling, general and administrative 9,302   14,423   20,020 29,133
Net loss (36,251) $ (41,036) (55,664) $ (52,190) (77,287) (107,854)
Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Other segment income, net 507   2,517   2,094 4,077
Lorigerlimab | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 10,547   11,009   19,425 20,625
MGC030 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 5,666   1,636   8,172 4,911
MGC028 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 4,742   9,678   8,676 15,882
Vobramitanmab duocarmazine | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 4,386   12,038   12,653 21,706
Next-generation T-cell engagers | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 3,516   2,091   5,789 4,580
MGC026 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 2,961   3,895   8,914 7,852
MGD024 | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 2,715   2,154   4,907 4,939
ADC | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 2,058   3,041   3,857 4,364
Margetuximab | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development 437   2,868   756 5,982
Other programs | Main Segment            
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]            
Research and development $ 3,763   $ 3,322   $ 7,340 $ 6,919